CoChat

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics

Cronin-Fenton, Deirdre P., Damkier, Per · 2018 · Advances in Pharmacology
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/bs.apha.2018.03.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 109

  1. Ahern, 2010, Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue, Clinical Epidemiology, 2, 241, 10.2147/CLEP.S13811 · doi:10.2147/clep.s13811
  2. Ahern, 2011, Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors, Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 20, 1937, 10.1158/1055-9965.EPI-11-0419 · doi:10.1158/1055-9965.epi-11-0419
  3. Ahern, 2017, Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: Evaluating the importance of loss of heterozygosity, American Journal of Epidemiology, 185, 75, 10.1093/aje/kww178 · DOI
  4. Amiri-Kordestani, 2012, Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies, Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 15, 50, 10.1016/j.drup.2012.02.002 · DOI · Paper page
  5. Argalacsova, 2017, Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients, Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology, 22, 1217
  6. Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 · DOI · Paper page
  7. Baurley, 2010, Discovery of complex pathways from observational data, Statistics in Medicine, 29, 1998, 10.1002/sim.3962 · DOI
  8. Berry, 2013, CYP2D6 genotyping and the use of tamoxifen in breast cancer, Journal of the National Cancer Institute, 105, 1267, 10.1093/jnci/djt221 · doi:10.1093/jnci/djt221
  9. Berry, 2014, Response, Journal of the National Cancer Institute, 106, 10.1093/jnci/dju065 · doi:10.1093/jnci/dju065
  10. Biglia, 2005, Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors, Maturitas, 52, 78, 10.1016/j.maturitas.2005.01.001 · DOI
  11. Borges, 2010, Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients, Journal of Clinical Pharmacology, 50, 450, 10.1177/0091270009359182 · doi:10.1177/0091270009359182
  12. Borges, 2006, Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment, Clinical Pharmacology and Therapeutics, 80, 61, 10.1016/j.clpt.2006.03.013 · DOI · Paper page
  13. Burger, 2008, Cycle and hormone changes during perimenopause: The key role of ovarian function, Menopause (New York, N.Y.), 15, 603, 10.1097/gme.0b013e318174ea4d · DOI · Paper page
  14. Buzdar, 2002, Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer, Breast Cancer Research and Treatment, 73, 161, 10.1023/A:1015229630260 · DOI
  15. Buzdar, 2006, Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial, The Lancet Oncology, 7, 633, 10.1016/S1470-2045(06)70767-7 · DOI · Paper page
  16. Buzdar, 1988, Phase II evaluation of Ly156758 in metastatic breast cancer, Oncology, 45, 344, 10.1159/000226637 · doi:10.1159/000226637
  17. Chamnanphon, 2013, Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen, Pharmacogenomics and Personalized Medicine, 6, 37
  18. Chubak, 2016, Breast cancer recurrence in relation to antidepressant use, Cancer Causes & Control: CCC, 27, 125, 10.1007/s10552-015-0689-y · DOI
  19. Cronin-Fenton, 2013, Metabolism and transport of tamoxifen in relation to its effectiveness: New perspectives on an ongoing controversy, Future Oncology, 10, 107, 10.2217/fon.13.168 · DOI
  20. Cronin-Fenton, 2010, Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: Risk of breast cancer recurrence and mortality, Future Oncology, 6, 877, 10.2217/fon.10.65 · DOI
  21. Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1 · DOI · Paper page
  22. De Ameida Melo, 2016, CYP2D6 gene polymorphisms in brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence, Biomedical Reports, 5, 574, 10.3892/br.2016.771 · doi:10.3892/br.2016.771
  23. Deitcher, 2004, The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: A systematic review, Cancer, 101, 439, 10.1002/cncr.20347 · DOI · Paper page
  24. Demissie, 2001, Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women, Journal of Clinical Oncology, 19, 322, 10.1200/JCO.2001.19.2.322 · DOI · Paper page
  25. Deng, 2001, Population admixture may appear to mask, change or reverse genetic effects of genes underlying complex traits, Genetics, 159, 1319, 10.1093/genetics/159.3.1319 · DOI
  26. Deshmane, 2007, Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25, 4967, 10.1200/JCO.2006.09.5992 · DOI
  27. Dezentje, 2015, CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects, Breast Cancer Research and Treatment, 153, 583, 10.1007/s10549-015-3562-5 · DOI
  28. Dezentje, 2013, CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial, Breast Cancer Research and Treatment, 140, 363, 10.1007/s10549-013-2619-6 · DOI
  29. Donneyong, 2016, Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: Multi-database cohort study, BMJ (Clinical Research Ed.), 354, i5014
  30. 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, Lancet, 365, 1687
  31. Ellsworth, 2003, High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer, Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 12, 915
  32. Fan, 2009, Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: Evidence from in vitro breast cancer cell models, Endocrinology, 150, 2036, 10.1210/en.2008-1195 · DOI
  33. Fisher, 2005, Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study, The Journal of the National Cancer Institute, 97, 1652, 10.1093/jnci/dji372 · DOI · Paper page
  34. Freour, 2017, Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy, European Journal of Cancer (Oxford, England: 1990), 74, 1, 10.1016/j.ejca.2016.12.008 · DOI
  35. Gaedigk, 2013, Complexities of CYP2D6 gene analysis and interpretation, International Review of Psychiatry (Abingdon, England), 25, 534, 10.3109/09540261.2013.825581 · DOI · Paper page
  36. Gjerde, 2008, Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism, Annals of Oncology, 19, 56, 10.1093/annonc/mdm434 · doi:10.1093/annonc/mdm434
  37. Goetz, 2008, Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response, Clinical Pharmacology and Therapeutics, 83, 160, 10.1038/sj.clpt.6100367 · DOI · Paper page
  38. Goetz, 2005, Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes, Journal of Clinical Oncology, 23, 9312, 10.1200/JCO.2005.03.3266 · DOI · Paper page
  39. Goetz, 2017, First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 3391, 10.1200/JCO.2017.73.3246 · DOI
  40. Goetz, 2014, Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for germline pharmacogenetic studies, Journal of the National Cancer Institute, 107, 10.1093/jnci/dju401 · doi:10.1093/jnci/dju401
  41. Gradishar, 2000, Effects of high dose raloxifene in selected patients with advanced breast carcinoma, Cancer, 88, 2047, 10.1002/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E · doi:10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co;2-e
  42. Gray, R. G., Rea, D. W., Handley, K., Marshall, A., Pritchard, M. G., Perry, P.,… (2008). aTTom (adjuvant tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results. [Abstract]. Journal of Clinical Oncology (Meeting Abstracts), 26 513. · DOI
  43. Haque, 2015, Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors, Journal of the National Cancer Institute, 108, 10.1093/jnci/djv337 · DOI · Paper page
  44. Hayes, 1995, Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 13, 2556, 10.1200/JCO.1995.13.10.2556 · DOI · Paper page
  45. Helland, 2017, Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients, Breast Cancer Research: BCR, 19, 125, 10.1186/s13058-017-0916-4 · DOI
  46. Henry, 2009, Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort, Breast Cancer Research and Treatment, 117, 571, 10.1007/s10549-009-0309-1 · DOI
  47. Hertz, 2017, CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: Results from a population-based study, Breast Cancer Research and Treatment, 166, 277, 10.1007/s10549-017-4400-8 · DOI
  48. Hicks, 2013, Beta-blocker usage and colorectal cancer mortality: A nested case-control study in the UK clinical practice research datalink cohort, Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 24, 3100, 10.1093/annonc/mdt381 · DOI
  49. Hicks, 2014, Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization, Current Drug Metabolism, 15, 218, 10.2174/1389200215666140202215316 · doi:10.2174/1389200215666140202215316
  50. Hirano, 2001, Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 7, 876
  51. Hu, 2016, Functional characterization of 22 novel CYP2D6 variants for the metabolism of tamoxifen, The Journal of Pharmacy and Pharmacology, 68, 819, 10.1111/jphp.12556 · DOI · Paper page
  52. International Breast Cancer Study Group, 2004, Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of international breast cancer study group trials 12-93 and 14-93, Annals of Oncology: Official Journal of the European Society for Medical Oncology, 15, 1749, 10.1093/annonc/mdh463 · DOI
  53. Iusuf, 2011, P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration, The Journal of Pharmacology and Experimental Therapeutics, 337, 710, 10.1124/jpet.110.178301 · DOI
  54. Jin, 2005, CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment, The Journal of the National Cancer Institute, 97, 30, 10.1093/jnci/dji005 · DOI · Paper page
  55. Johansson, 2016, A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen, Breast Cancer Research and Treatment, 159, 97, 10.1007/s10549-016-3932-7 · doi:10.1007/s10549-016-3932-7
  56. Johnson, 2015, Loss of heterozygosity at the CYP2D6 locus in breast cancer: Implications for tamoxifen pharmacogenetic studies, Journal of the National Cancer Institute, 107, 10.1093/jnci/dju437 · doi:10.1093/jnci/dju437
  57. Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Research and Treatment, 85, 151, 10.1023/B:BREA.0000025406.31193.e8 · DOI · Paper page
  58. Jordan, 2008, Tamoxifen: Catalyst for the change to targeted therapy, European Journal of Cancer (Oxford, England: 1990), 44, 30, 10.1016/j.ejca.2007.11.002 · DOI · Paper page
  59. Jordan, 1977, A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity, The Journal of Endocrinology, 75, 305, 10.1677/joe.0.0750305 · DOI · Paper page
  60. Jordan, 2011, The St. Gallen prize lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: Consequences and opportunities, Breast (Edinburgh, Scotland), 20, S1
  61. 1996, Journal of the National Cancer Institute, 88, 1543, 10.1093/jnci/88.21.1543 · DOI · Paper page
  62. Juurlink, 2016, Revisiting the drug interaction between tamoxifen and SSRI antidepressants, BMJ (Clinical Research Ed.), 354, i5309
  63. Karle, 2013, Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer, Breast Cancer Research and Treatment, 139, 553, 10.1007/s10549-013-2565-3 · doi:10.1007/s10549-013-2565-3
  64. Kiyotani, 2010, Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients, Journal of Clinical Oncology, 28, 1287, 10.1200/JCO.2009.25.7246 · DOI · Paper page
  65. Kiyotani, 2008, Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy, Cancer Science, 99, 995, 10.1111/j.1349-7006.2008.00780.x · doi:10.1111/j.1349-7006.2008.00780.x
  66. Lai, 2012, Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability—Considerations for drug development, Expert Opinion on Drug Metabolism & Toxicology, 8, 723, 10.1517/17425255.2012.678048 · DOI
  67. Lash, 2008, Comment on 'impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy', Cancer Science, 99, 1706, 10.1111/j.1349-7006.2008.00864.x · doi:10.1111/j.1349-7006.2008.00864.x
  68. Lash, 2009, Immortal person-time in studies of cancer outcomes, Journal of Clinical Oncology, 27, e55, 10.1200/JCO.2009.24.1877 · DOI
  69. Lash, 2011, CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark, The Journal of the National Cancer Institute, 103, 489, 10.1093/jnci/djr010 · DOI
  70. Lash, 2009, Genotype-guided tamoxifen therapy: Time to pause for reflection?, The Lancet Oncology, 10, 825, 10.1016/S1470-2045(09)70030-0 · DOI
  71. Lazarus, 2009, Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen, The Annals of the New York Academy of Sciences, 1155, 99, 10.1111/j.1749-6632.2009.04114.x · DOI
  72. Lei, 2016, Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population, American Journal of Translational Research, 8, 3585
  73. Leslie, 2005, Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicology and Applied Pharmacology, 204, 216, 10.1016/j.taap.2004.10.012 · DOI · Paper page
  74. Lien, 1988, Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile, Cancer Research, 48, 2304
  75. Lim, 2005, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen, Cancer Chemotherapy and Pharmacology, 55, 471, 10.1007/s00280-004-0926-7 · DOI · Paper page
  76. Madlensky, 2011, Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes, Clinical Pharmacology and Therapeutics, 89, 718, 10.1038/clpt.2011.32 · DOI · Paper page
  77. Marcath, 2017, Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment, Pharmacogenetics and Genomics, 27, 402, 10.1097/FPC.0000000000000311 · DOI
  78. Markkula, 2014, No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients, Acta Oncologica (Stockholm, Sweden), 53, 195, 10.3109/0284186X.2013.840739 · doi:10.3109/0284186x.2013.840739
  79. Martins, 2014, Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in Sao Luis, Brazil, and its association with prognostic factors and disease-free survival, Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas e Biologicas, 47, 1008, 10.1590/1414-431X20143761 · doi:10.1590/1414-431x20143761
  80. Mwinyi, 2014, Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy, Cancer Chemotherapy and Pharmacology, 73, 1181, 10.1007/s00280-014-2453-5 · doi:10.1007/s00280-014-2453-5
  81. Pharoah, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial and re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, Journal of the National Cancer Institute, 104, 1263, 10.1093/jnci/djs312 · DOI
  82. Powers, 2016, Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9, CYP2C19, and ABCB1, Journal of Clinical Pharmacology, 56, 1570, 10.1002/jcph.771 · DOI
  83. Rae, 2003, Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples, Pharmacogenetics, 13, 501, 10.1097/00008571-200308000-00008 · DOI
  84. Rae, 2012, CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, Journal of the National Cancer Institute, 104, 452, 10.1093/jnci/djs126 · DOI · Paper page
  85. Rae, 2013, Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA, Journal of the National Cancer Institute, 105, 1332, 10.1093/jnci/djt204 · doi:10.1093/jnci/djt204
  86. Reed, 2011, The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment, Pharmacogenomics, 12, 1465, 10.2217/pgs.11.84 · DOI
  87. Regan, 2012, CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial, Journal of the National Cancer Institute, 104, 441, 10.1093/jnci/djs125 · DOI · Paper page
  88. Saladores, 2015, Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer, The Pharmacogenomics Journal, 15, 84, 10.1038/tpj.2014.34 · DOI · Paper page
  89. Sanchez Spitman, 2017, Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism, European Journal of Clinical Pharmacology, 73, 1589, 10.1007/s00228-017-2323-2 · DOI
  90. Sanchez-Spitman, 2017, The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen, Pharmacogenomics, 18, 1125, 10.2217/pgs-2017-0080 · doi:10.2217/pgs-2017-0080
  91. Schneider, 2006, Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes, Breast Cancer Research and Treatment, 96, 209, 10.1007/s10549-005-9003-0 · doi:10.1007/s10549-005-9003-0
  92. Sensorn, 2013, Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of thai breast cancer patients treated with tamoxifen, Pharmacogenomics and Personalized Medicine, 6, 93, 10.2147/PGPM.S44006 · DOI
  93. Sheng, 1996, Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas, British Journal of Cancer, 73, 144, 10.1038/bjc.1996.27 · DOI
  94. Sherman, 1979, Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women, The Journal of Clinical Investigation, 64, 398, 10.1172/JCI109475 · DOI
  95. Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, Journal of Clinical Oncology, 28, 2768, 10.1200/JCO.2009.23.8931 · DOI · Paper page
  96. Stanton, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial, Journal of the National Cancer Institute, 104, 1265, 10.1093/jnci/djs305 · DOI
  97. Stearns, 2003, Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine, The Journal of the National Cancer Institute, 95, 1758, 10.1093/jnci/djg108 · DOI · Paper page
  98. Sukasem, 2012, Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: A microarray-based study in Thailand, Asian Pacific Journal of Cancer Prevention: APJCP, 13, 4549, 10.7314/APJCP.2012.13.9.4549 · doi:10.7314/apjcp.2012.13.9.4549
  99. Swerdlow, 2005, Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study, The Journal of the National Cancer Institute, 97, 375, 10.1093/jnci/dji057 · DOI · Paper page
  100. Teft, 2011, Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1), Drug Metabolism and Disposition: The Biological Fate of Chemicals, 39, 558, 10.1124/dmd.110.036160 · DOI
  101. Teh, 2012, The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1, The AAPS Journal, 14, 52, 10.1208/s12248-011-9313-6 · DOI
  102. Thompson, 2011, Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy, Breast Cancer Research and Treatment, 125, 279, 10.1007/s10549-010-1139-x · DOI
  103. Valachis, 2016, Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: A population-based study, Breast Cancer Research and Treatment, 159, 293, 10.1007/s10549-016-3928-3 · DOI
  104. Wheeler, 2013, Cancer pharmacogenomics: Strategies and challenges, Nature Reviews. Genetics, 14, 23, 10.1038/nrg3352 · DOI · Paper page
  105. Xie, 2006, Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer, Carcinogenesis, 27, 307, 10.1093/carcin/bgi215 · doi:10.1093/carcin/bgi215
  106. Xu, 2008, Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment, Annals of Oncology, 19, 1423, 10.1093/annonc/mdn155 · doi:10.1093/annonc/mdn155
  107. Yazdi, 2015, CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients, Asian Pacific Journal of Cancer Prevention: APJCP, 16, 6783, 10.7314/APJCP.2015.16.15.6783 · doi:10.7314/apjcp.2015.16.15.6783
  108. Zanger, 2004, Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry, Naunyn-Schmiedebergs Archives of Pharmacology, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
  109. Zhang, 2015, Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy, Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 21, 563, 10.12659/MSM.893473 · DOI

Cited by

See all 42

Metadata

Authors
Cronin-Fenton, D. P., & Damkier, P.
Venue
Advances in Pharmacology
Publisher
Elsevier
Published
2018
Pages
65-91
ISSN
1054-3589
Cited by
42
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. https://app.cochat.ai/papers/10.1016/bs.apha.2018.03.001
The paper
Cronin-Fenton, D. P., & Damkier, P. (2018). Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2018.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.